ORPHA:199251
Ledderhose disease
Also known as: Plantar fibromatosis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
532
72.3th percentile
Trials
4
Interventional, condition-specific
Researchers
964
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, benign, superficial fibromatosis disease characterized by single or multiple, uni- or bilateral, slow-growing, round, firm nodules typically located on the medial portion of the plantar aponeurosis, with no calcification. Patients are often asymptomatic or may present with foot pain, difficulty to walk or stand and, rarely, toe contractures. Histopathology reveals dense fibrocellular tissue with parallel and nodular arrays of fibrocytes and fibrillar collagen with a distinctive cork-screw morphology and no atypia.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0004684
- MeSH:C537000
- UMLS:C0158360
- NCIT:C4680
Additional Mondo synonyms (6)
Ledderhose's disease · Lederhose disease · plantar fibromatosis · plantar part of pes superficial Fibromatosis · plantar part of pes superficial fibromatosis · superficial fibromatosis of plantar part of pes
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
532 matched papers (257 in last 10 years) Source
- Phenotype characterisedPresent
5 HPO annotations (e.g. Arthralgia; Paresthesia; Peripheral neuropathy) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
4 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
5
Associated phenotypes · MONDO:0004684
- Arthralgia
- Paresthesia
- Peripheral neuropathy
- Subcutaneous nodule
- Lack of skin elasticity
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
532
532 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
532 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
257 in the last 10 years · medium confidence · 72.3th percentile (publications denominator)
Phrase hits: 532 · MeSH hits: 0
Who's working on it?
964
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Özçakar L5 papers · 2025
Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Ankara, Turkey.
Papers in Europe PMC - 02Werker PMN5 papers · 2023
From the Departments of Urology and Plastic and Reconstructive Surgery, University of Groningen and University Medical Center Groningen.
Papers in Europe PMC - 03de Haan A4 papers · 2023
University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, Groningen, the Netherlands. Electronic address: a.de.haan01@umcg.nl.
Papers in Europe PMC - 04Langendijk JA4 papers · 2023
University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, Groningen, the Netherlands.
Papers in Europe PMC - 05Steenbakkers RJHM4 papers · 2023
University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, Groningen, the Netherlands.
Papers in Europe PMC - 06van Nes JGH4 papers · 2023
Radiotherapeutisch Instituut Friesland, Leeuwarden, the Netherlands.
Papers in Europe PMC - 07Kara M3 papers · 2025
Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Ankara, Turkey.
Papers in Europe PMC - 08Abdulsalam AJ2 papers · 2025
Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Ankara, Turkey, Department of Physical Medicine and Rehabilitation, Mubarak Alkabeer Hospital, Kuwait. dr.ahmad.j.abdulsalam@gmail.com.
Papers in Europe PMC - 09Bianchi S2 papers · 2014
Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital, Basel, Switzerland.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
4
interventional trials for this specific condition
4 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 11 September 2026
4 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 88.1th percentile).
medium confidence · 88.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
4 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Ledderhose disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Ledderhose disease" OR "Plantar fibromatosis" OR "Ledderhose's disease" OR "Lederhose disease" OR "plantar part of pes superficial Fibromatosis" OR "plantar part of the pes superficial Fibromatosis" OR "superficial fibromatosis of plantar part of pes" OR "superficial fibromatosis of the plantar part of the pes"
MeSH descriptor terms unioned into the query: [OBSOLETE] Ledderhose disease
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Ledderhose disease" OR "Plantar fibromatosis" OR "Ledderhose's disease" OR "Lederhose disease" OR "plantar part of pes superficial Fibromatosis" OR "plantar part of the pes superficial Fibromatosis" OR "superficial fibromatosis of plantar part of pes" OR "superficial fibromatosis of the plantar part of the pes" OR "[OBSOLETE] Ledderhose disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 4 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:09:20.943Z